Polymorphisms in the glutamate transporter gene SLC1A1 and obsessive-compulsive symptoms induced by second-generation antipsychotic agents

Psychiatric Genetics

Volumn 22, Issue 5, 2012, Pages 245-252

  Schirmbeck, Frederike ^a   Nieratschker, Vanessa ^a   Frank, Josef ^a   Englisch, Susanne ^a   Rausch, Franziska ^a   Meyer Lindenberg, Andreas ^a   Rietschel, Marcella ^a   Zink, Mathias ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

antipsychotic; clozapine; compulsive; genetics; obsessive; schizophrenia

Indexed keywords

CLOZAPINE; EXCITATORY AMINO ACID TRANSPORTER 3;

ADULT; AGE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; DEMOGRAPHY; EXCITATORY AMINO ACID TRANSPORTER 3; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INHERITANCE PATTERNS; LOGISTIC MODELS; MALE; MODELS, GENETIC; OBSESSIVE-COMPULSIVE DISORDER; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84865736503     PISSN: 09558829     EISSN: 14735873     Source Type: Journal    
DOI: 10.1097/YPG.0b013e328353fbee     Document Type: Article

References (47)

1. Achim AM, Maziade M, Raymond E, Olivier D, Merette C, Roy MA (2011). How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 37:811-821.
2. Albelda N, Bar-On N, Joel D (2010). The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder. Psychopharmacology 210:13-24.
3. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL (2006). Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 63:769-776.
4. Baker RW, Chengappa KN, Baird JW, Steingard S, Christ MA, Schooler NR (1992). Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry 53:439-442.
5. Bienvenu OJ,Wang Y, Shugart YY,Welch JM, Grados MA, Fyer AJ, et al. (2009). Sapap3 and pathological grooming in humans: Results from the OCD collaborative genetics study. Am J Med Genet Neuropsychiatr Genet 710-720.
6. Buckley PF, Miller BJ, Lehrer DS, Castle DJ (2009). Psychiatric comorbidities and schizophrenia. Schizophr Bull 35:383-402.
7. Charnay Y, Leger L (2010). Brain serotonergic circuitries. Dialogues Clin Neurosci 12:471-487.
8. Coric V.,Taskiran S.,Pittenger C.,Wasylink S.,Mathalon D.H.,Valentine G.,et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial ,58,424-428
9. Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, et al. (2005). Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Biol Psychiatry 58:424-428. De Haan L, Linszen DH, Gorsira R (1999). Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J Clin Psychiatry 60:364-365.
10. De Haan L, Beuk N, Hoogenboom B, Dingemans P, Linszen D (2002). Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: A prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry 63:104-107.
11. De Haan L, Hoogeboom B, Beuk N, Wouters L, Dingemans PM, Linszen DH (2006). Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients. Psychopharmacol Bull 39:25-30.
12. De Haan L, Dudek-Hodge C, Verhoeven Y, Denys D (2009). Prevalence of psychotic disorders in patients with obsessive-compulsive disorder. CNS Spectr 14:415-417.
13. Deng X, Shibata H, Takeuchi N, Rachi S, Sakai M, Ninomiya H, et al. (2007). Association study of polymorphisms in the glutamate transporter genes SLC1A1, SLC1A3, and SLC1A6 with schizophrenia. Am J Med Genet Neuropsychiatr Genet 144B:271-278.
14. Dickel DE, Veenstra-VanderWeele J, Cox NJ,Wu X, Fischer DJ, Van Etten-Lee M, et al. (2006). Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 63:778-785.
15. El Mansari M, Blier P (2006). Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 30:362-373.
16. Hwang MY, Kim SW, Yum SY, Opler LA (2009). Management of schizophrenia with obsessive-compulsive features. Psychiatr Clin North Am 32:835-851.
17. Joel D (2006). Current animal models of obsessive compulsive disorder: A critical review. Prog Neuropsychopharmacol Biol Psychiatry 30:374-388.
18. Ju YS, Kim JI, Kim S, Hong D, Park H, Shin JY, et al. (2011). Extensive genomic and transcriptional diversity identified through massively parallel DNA and RNA sequencing of eighteen Korean individuals. Nat Genet 43:745-752.
19. Kwon JS, Joo YH, Nam HJ, Lim M, Cho EY, Jung MH, et al. (2009). Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch Gen Psychiatry 66:1233-1241.
20. Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, et al. (2006). N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology 184: 4-256.
21. Lim M, Park DY, Kwon JS, Joo YH, Hong KS (2007). Prevalence and clinical characteristics of obsessive-compulsive symptoms associated with atypical antipsychotics. J Clin Psychopharmacol 27:712-713.
22. Lin SK, Su SF, Pan CH (2006). Higher plasma drug concentration in clozapinetreated schizophrenic patients with side effects of obsessive/compulsive symptoms. Ther Drug Monit 28:303-307.
23. Meyer-Lindenberg A (2010). From maps to mechanisms through neuroimaging of schizophrenia. Nature 468:194-202.
24. Mukhopadhaya K, Krishnaiah R, Taye T, Nigam A, Bailey AJ, Sivakumaran T, et al. (2009). Obsessive-compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: A cause for clinical concern. J Psychopharmacol 23:6-13.
25. Nicolini H, Arnold P, Nestadt G, Lanzagorta N, Kennedy JL (2009). Overview of genetics and obsessive-compulsive disorder. Psychiatry Res 170:7-14.
26. Pauls DL (2010). The genetics of obsessive-compulsive disorder: A review. Dialogues Clin Neurosci 12:149-163.
27. Pittenger C, Krystal JH, Coric V (2006). Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 3:69-81.
28. Pogarell O, Hamann C, Poepperl G, Juckel G, Chouker M, Zaudig M, et al. (2003). Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol Psychiatry 54:1406-1413.
29. Poyurovsky M, Weizman A, Weizman R (2004). Obsessive-compulsive disorder in schizophrenia: Clinical characteristics and treatment. CNS Drugs 18: 989-1010.
30. Poyurovsky M,Weizman R,Weizman A, Koran L, Poyurovsky M,Weizman R, et al. (2005). Memantine for treatment-resistant OCD. Am J Psychiatry 162: 2191-2192.
31. Poyurovsky M, Glick I, Koran LM (2010). Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. J Psychopharmacol 24:861-866.
32. Reznik I, Yavin I, Stryjer R, Spivak B, Gonen N, Strous R, et al. (2004). Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: A case series study. Pharmacopsychiatry 37:52-56.
33. Rosenberg DR, Hanna GL (2000). Genetic and imaging strategies in obsessive - compulsive disorder: Potential implications for treatment development. Biol Psychiatry 48:1210-1222.
34. Rosenberg DR, Mirza Y, Russell A, Tang J, Smith JM, Banerjee SP, et al. (2004). Reduced anterior Cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 43:1146-1153.
35. Schirmbeck F, Zink M (2011b). Clozapine-induced obsessive-compulsive symptoms in schizophrenia: A critical review. Curr Neuropharmacol 10:88-95.
36. Schirmbeck F, Esslinger C, Rausch F, Englisch S, Meyer-Lindenberg A, Zink M (2011a). Antiserotonergic antipsychotics are associated with obsessivecompulsive symptoms in schizophrenia. PsycholMed 41:2361-2374.
37. Schönfelder S, Schirmbeck F, Waltereit R, Englisch S, Zink M (2011). Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia. Clin Neuropharmacol 34:256-257.
38. Shugart YY,Wang Y, Samuels JF, Grados MA, Greenberg BD, Knowles JA, et al. (2009). A family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder in 378 families. Am J d Genet Neuropsychiatr Genet 150B:886-892.
39. Starck G, Ljungberg M, Nilsson M, Jonsson L, Lundberg S, Ivarsson T, et al. (2008). A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: Relationship between metabolite concentrations and symptom severity. J Neural Transm 115:1051-1062.
40. Stewart SE, Fagerness JA, Platko J, Smoller JW, Scharf JM, Illmann C, et al. (2007). Association of the SLC1A1 glutamate transporter gene and obsessivecompulsive disorder. Am J Med Genet Neuropsychiatr Genet 144B:1027-1033.
41. Tate SK, Goldstein DB (2008). Will tomorrow's medicines work for everyone? In: Koenig BA, editor. Revisiting race in a genomic age. Piscataway, NJ: Rutgers University Press. pp. 102-128.
42. Veenstra-VanderWeele J, Kim SJ, Gonen D, Hanna GL, Leventhal BL, Cook EH Jr (2001). Genomic organization of the SLC1A1/EAAC1 gene and mutation screening in early-onset obsessive-compulsive disorder. Mol Psychiatry 6:160-167.
43. Wendland JR, Moya PR, Timpano KR, Anavitarte AP, Kruse MR, Wheaton MG, et al. (2009). A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. Arch Gen Psychiatry 66:408-416.
44. Whiteside SP, Port JD, Deacon BJ, Abramowitz JS (2006). A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety. Psychiatry Res 146:137-147.
45. Wu K, Hanna GL, Rosenberg DR, Arnold PD (2011). The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav 100:726-735.
46. Yang XW, Lu XH (2011). Molecular and cellular basis of obsessive-compulsive disorder-like behaviors: Emerging view from mouse models. Curr Opin Neurol 24:114-118.
47. Zoellner S, Pritchard JK (2007). Overcoming the winners curse: Estimating penetrance parameters from Case-Control Data. Am J Hum Genet 80: 605-615.